Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$20.82 +3.8%	$19.80	$14.40 ▼ $47.00	$1.38B	1.33	940,207 shs	724,877 shs
HSKA Heska	$119.99	$119.09	$57.83 ▼ $120.03	$1.31B	1.58	241,932 shs	N/A
MYGN Myriad Genetics	$5.07 +1.8%	$5.61	$3.81 ▼ $29.30	$467.34M	1.84	1.24 million shs	1.99 million shs
VIVO Meridian Bioscience	$33.97	$33.70	$20.35 ▼ $34.38	$1.50B	0.23	973,737 shs	N/A

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	0.00%	+2.31%	+1.61%	+6.01%	-39.93%
HSKA Heska	0.00%	0.00%	0.00%	0.00%	0.00%
MYGN Myriad Genetics	0.00%	-2.31%	+13.93%	-49.35%	-78.79%
VIVO Meridian Bioscience	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.923 of 5 stars	4.4	3.0	0.0	0.0	3.2	0.0	0.0
HSKA Heska	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	4.0407 of 5 stars	4.1	1.0	0.0	4.1	1.9	1.7	0.6
VIVO Meridian Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	140.69% Upside
HSKA Heska	0.00	N/A	N/A	N/A
MYGN Myriad Genetics	2.13	Hold	$14.38	183.72% Upside
VIVO Meridian Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HSKA, VIVO, MYGN, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	196.87	N/A	N/A	$11.26 per share	1.85
HSKA Heska	$257.31M	5.09	$1.69 per share	70.99	$39.00 per share	3.08
MYGN Myriad Genetics	$837.60M	0.56	$1.00 per share	5.07	$7.70 per share	0.66
VIVO Meridian Bioscience	$333.02M	4.49	$1.78 per share	19.13	$8.41 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
HSKA Heska	-$19.89M	-$1.93	N/A	83.33	N/A	-7.86%	0.94%	0.67%	N/A
MYGN Myriad Genetics	-$127.30M	-$1.12	N/A	N/A	N/A	-12.20%	-4.95%	-3.39%	8/5/2025 (Estimated)
VIVO Meridian Bioscience	$42.46M	$0.97	35.02	∞	N/A	12.70%	16.74%	13.09%	N/A

Latest HSKA, VIVO, MYGN, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
HSKA Heska	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
VIVO Meridian Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	21.67	21.67
HSKA Heska	0.23	5.64	4.12
MYGN Myriad Genetics	0.08	1.90	1.71
VIVO Meridian Bioscience	0.07	3.63	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
HSKA Heska	99.01%
MYGN Myriad Genetics	99.02%
VIVO Meridian Bioscience	89.72%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
HSKA Heska	12.30%
MYGN Myriad Genetics	2.40%
VIVO Meridian Bioscience	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
HSKA Heska	808	10.91 million	9.57 million	Not Optionable
MYGN Myriad Genetics	2,700	92.18 million	89.97 million	Optionable
VIVO Meridian Bioscience	702	44.01 million	43.00 million	Optionable

HSKA, VIVO, MYGN, and CLDX Headlines

Recent News About These Companies

Meridian Bioscience Introduces New Enzyme Stabilization Services for Molecular Diagnostics

April 24, 2025 | finance.yahoo.com

Meridian Bioscience Inc (VIVO)

April 10, 2025 | uk.investing.com

India's smartphone mkt grows 6%, Vivo tops

November 13, 2024 | rediff.com

Meridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to Sustainability

November 7, 2024 | finance.yahoo.com

Meridian Bioscience Gets $500K Top Prize in POC Blood Lead Test Challenge

October 28, 2024 | 360dx.com

Precision BioSciences Launches First Hepatitis B Gene-Editing Trial

October 26, 2024 | precisionmedicineonline.com

Will iQOO 13 launch at same price as iQOO 12? New leak provides major hint

October 25, 2024 | msn.com

Editas strengthens in vivo gene therapy strategy via $238M LNP tech pact with Genevant

October 22, 2024 | fiercebiotech.com

Vivo and Arm collaborate on chip technology innovation, launch joint lab

October 21, 2024 | digitimes.com

vivo and Arm collaborate on chip technology innovation with the unveiling of the vivo Arm Joint Lab

October 18, 2024 | malaysiasun.com

Meridian Growth Legacy MERDX

October 17, 2024 | morningstar.com

Serán Bioscience snags investment from Bain Capital Life Sciences

September 17, 2024 | pehub.com

Vivo T3 Ultra launch on September 12 – check what’s in store for India market

September 6, 2024 | financialexpress.com

Vivo V40 vs Realme GT 6T: How the two mid-range smartphones compare

August 11, 2024 | msn.com

Fast-growing MBX Biosciences raises another $63.5 million in funding

August 6, 2024 | ibj.com

Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic Manufacturers

July 23, 2024 | finance.yahoo.com

Grant supports Lift Biosciences’ evaluation of IMAN cell therapies in humanized in vivo model systems

May 17, 2024 | bioworld.com

Biomerica, Inc. (BMRA)

May 11, 2024 | finance.yahoo.com

Vivo X100s Pro with new Dimensity 9300 Plus chip could be launching soon

March 24, 2024 | gizmochina.com

Vivo V30 Pro review: Flagship-grade imaging system in a slender form factor

March 13, 2024 | business-standard.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSKA, VIVO, MYGN, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$20.82 +0.76 (+3.79%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$20.17 -0.65 (-3.14%)

As of 06/18/2025 07:50 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Heska NASDAQ:HSKA

Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.

Myriad Genetics NASDAQ:MYGN

$5.07 +0.09 (+1.81%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$5.17 +0.10 (+1.97%)

As of 06/18/2025 07:11 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Meridian Bioscience NASDAQ:VIVO

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time